Active Biotech AB (publ) (FRA:BTPC)

Germany flag Germany · Delayed Price · Currency is EUR
0.0019
-0.0049 (-72.06%)
Last updated: Jan 6, 2026, 8:06 AM CET
-68.33%
Market Cap10.90M
Revenue (ttm)n/a
Net Income (ttm)-3.48M
Shares Outn/a
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume18,213
Open0.0019
Previous Close0.0068
Day's Range0.0019 - 0.0019
52-Week Range0.0016 - 0.0307
Betan/a
RSI49.64
Earnings DateFeb 12, 2026

About Active Biotech AB

Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvir... [Read more]

Industry Pharmaceutical Preparations
Founded 1983
Employees 6
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol BTPC
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

Active Biotech AB: Active Biotech's patent related to a pharmaceutical formulation of tasquinimod will be granted in the US

Lund, November 25, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent and Trademark Office (USPTO) has issued a notification that the company's patent application rela...

6 weeks ago - Finanz Nachrichten